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Objectives: Upon completion of this article, the reader will be
able to describe themechanism of action of available ablation
modalities and data supporting their use.
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Renalmalignancy is among themost frequent cancers in both
men and women, with approximately 65,150 new cases diag-
nosed in theUnitedStates in2013.1Ninetypercentof these cases
represent renal cell carcinoma (RCC), with transitional cell
carcinoma of the renal pelvis comprising the remainder.2 Before
the advent of modern cross-sectional imaging, kidney cancer
was usually detected in the advanced stages, when tumor size
and aggressive characteristics necessitated treatment with radi-
cal nephrectomy. However, in the early 1990s, the incidence of
RCCdemonstrateda steady rise, due inpart todetectionof stage I
disease on increasingly used cross-sectional abdominal imaging
studies.3 Recently, the incidence of new RCC has plateaued in
most western societies4; however, the rise in detection of small
renal masses (SRMs) has created a treatment predicament.
Because of the heterogeneous tumor biology of SRMs, several
different treatment options exist, ranging from active surveil-
lance to ablation to partial or radical nephrectomy.5 This large
range of treatment options poses a problem to practitioners and
patients alike. As a result, the American Urologic Association
(AUA)6 updated their guidelines for the treatment of stage I
disease in 2009.
Radical nephrectomy still represents the most commonly
used treatment for RCC4; however, there are data suggesting
that surgically induced chronic kidney disease may increase
cardiovascular and metabolic risk factors.7 In addition, there
has been a gradual shift toward nephron-sparing treatment
options, including partial nephrectomy and thermal ablation.
While partial nephrectomy shows similar oncologic control
to radical nephrectomy, it does so with an increased compli-
cation profile.8 Active surveillance has been listed as an
Keywords








Abstract Thermal ablative technologies have evolved considerably in the recent past and are now
an important component of current clinical guidelines for the treatment of small renal
masses. Both radiofrequency ablation and cryoablation have intermediate-term oncol-
ogic control that rivals surgical options, with favorable complication profiles. Studies
comparing cryoablation and radiofrequency ablation show no significant difference in
oncologic control or complication profile between the two modalities. Early data from
small series with microwave ablation have shown similar promising results. Newer
technologies including irreversible electroporation and high-intensity–focused ultra-
sound have theoretical advantages, but will require further research before becoming a
routine part of the ablation armamentarium. The purpose of this review article is to
discuss the current ablative technologies available, briefly review their mechanisms of
action, discuss technical aspects of each, and provide current data supporting their use.
Issue Theme Tumor Ablation; Guest
Editor, Charles T. Burke, MD, FSIR
Copyright © 2014 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
























































appropriate initial strategy in the AUA guidelines for SRMs;
however, this choice is usually unpopular with patients,
especially younger patients who would require lifelong
monitoring.
Ablative modalities use energy tissue interactions, rather
than excision, to destroy tumors and a surroundingmargin of
normal tissue while sparing renal parenchyma. Ablative
technologies have had steadily increasing usage for the
treatment of RCC and have the potential of becoming stan-
dard therapy for stage I renal tumors. While long-term
oncologic data supporting their use are limited, their use
has a special role in the treatment algorithm of stage I RCC.
Ablative procedures are best suited for patients with SRMs
who are advanced in age and have significant comorbidities,
or unable to undergo open or laparoscopic surgical interven-
tion. Current AUA guidelines suggest use of tumor ablation for
patients with substantial comorbidities and in patients with a
solitary kidney who are high risk for complete loss of renal
function after nephron-sparing surgery.6
Cryoablation
The use of cold to treat tumors is first credited to James
Arnott, who in the 19th century used topical cold temper-
atures to treat tumors of the cervix and breast.9 In the 20th
century, the use of liquid nitrogen-based cryotherapy became
an important element in the treatment of benign and malig-
nant prostatic conditions.10 While the first renal cryosurgery
was reported in 1968 by Lutzeyer and Lymberopoulos,11 it
was not until 1995 that Uchida et al reported the first use of
percutaneous cryoablation in a canine model using a nitro-
gen-based system.11,12 Subsequently, the introduction of
argon-based cryotherapy, first studied by Torre in 1975,13
then put into clinical practice in the 1990s,14 has allowed for
reduction in probe size, thus facilitating percutaneous appli-
cations for treating solid organ tumors.
Cryoablation is based on the Joule–Thomson effect, which
describes the cooling of a high-pressure gas as it travels
through a pinhole valve into a region of lower pressure.
Most gases, including nitrogen and argon, cool in such a
system. Thus, high-pressure argon, passing through a valve
in the tip of a cryoprobe, expands and cools to temperatures as
low as 185°C.15 Importantly, helium is one of the few gases
that warm when allowed to expand in such a fashion; there-
fore, it is used towarm the systemand facilitate probe removal.
Cryoablation causes tissue destruction by two major
mechanisms: direct cell injury and vascular injury.15–17 Ini-
tially, as the temperature in the tissue drops into the 0 to
20°C range, extracellular ice crystals form creating an
osmotic gradient and pulling water from the cells, resulting
in cellular dehydration. The increased intracellular electrolyte
concentration is often sufficient to destroy the cell15; howev-
er, this is augmented by additional cellular damage from ice
crystal formation, cell shrinkage, and direct damage to
membranes.17 As the temperatures drop further to below
20°C, intracellular ice crystals form, destroying the cell by
disruption of organelles and cell membranes, making cell
death almost certain.17 Ice crystal formation, both intracellu-
lar and extracellular, results in loss of water from the system
and leads to cell desiccation and death.16,17 It is interesting to
note that intracellular ice formation is most associated with
rapid cooling rates that are seen close to the cryoprobe, while
cellular dehydration is associated with slower rates of cool-
ing.15 Upon warming, ice crystals coalesce to form larger
crystals that disrupt cell membranes, a process known as
recrystallization.17 As the ice melts, briefly creating an extra-
cellular hypotonic environment, free extracellular water can
enter the damaged cells, increase the cell volume, and poten-
tially lead to cell rupture.15 Apoptosis, or gene-regulated
programmed cell death, has also been found to be a mecha-
nism of direct cellular injury, particularly at the periphery of
the lesion.16,18,19 In sum, the formation of intra- and extra-
cellular ice crystals leads to a cascade of events that directly
kills cells.15–17
While the direct cellular injury described earlier is fairly
immediate, a more delayed vascular injury occurs secondary
to failure of the microcirculation, vascular stasis, thrombosis,
and ultimately necrosis.15,17 Vasoconstriction is the first
vascular response to the initial freeze cycle, with an associat-
ed decrease in the flow of blood that ceases completely upon
freezing. With rewarming, vasodilation ensues briefly fol-
lowed by increased vascular permeability, edema, platelet
aggregation, and microthrombus formation.17 Free radical
propagation, neutrophil activation, and the release of toxic
enzymesmayplay a role in endothelial injury during the thaw
phase as well.18 The resultant ischemia renders the tissue
necrotic, except at the periphery of the target volume.15–17
Keys to successful cryoablation include proper monitoring
of the ablation, rapid cooling to lethal temperature, slow
thawing, and repetition of the freeze–thaw cycle.15 What
temperature is lethal remains a topic of debate, as it depends
on the water and electrolyte content of the tissue, and the
normal or malignant nature of the tissue.17 While temper-
atures of 40 to 50°C are thought to be critical for absolute
cell death after a single freeze–thaw cycle,15,17 temperatures
of 20 to 40°C are thought to be sufficient to cause cellular
death based on the makeup of most solid parenchymal
tumors.18,20 Recently, an animal model was used to identify
that the distance from the outer margin of the visualized ice
ball to the conservative (40°C) lethal isotherm for renal cell
cancer is approximately 6 mm.21 This corresponds to the
clinical recommendation of creating a volume of ice which
encompasses the tumor plus a 5- to 10-mm margin.22 Typi-
cally, three 1.7 mm cryoprobes placed 1.5 cm apart are
sufficient to ablate a 2-cm lesion, and five probes for a
3-cm tumor.22 Ideally, the cryoprobes are placed parallel to
one another, but at times anatomy may prohibit this and
other geometries must be employed (►Fig. 1). Increasing the
number of freeze–thaw cycles also has a beneficial effect on
death, as with each successive cycle, tissue cooling is quicker,
the frozen tissue volume is increased, and the zone of necrosis
is brought closer to the edge of the frozen volume.15 Typically,
two freeze–thaw cycles are used clinically.22,23
Cryoablation can be performed both surgically (open or
laparoscopic) and via a percutaneous approach. Several series
comparing surgical and percutaneous approaches have been
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performed. One recent single center, retrospective study
compared 54 surgically treated tumors with 154 percutane-
ously treated lesions, showing similar oncologic control
between the two groups, but a reduced length in hospital
stay in the percutaneous group.24 Other series have shown
similar results with oncologic control comparable between
surgical and percutaneous groups, but with lower complica-
tion profile, reduced cost, and reduced hospital stay in the
percutaneous group.25–29
Excluding direct puncture by the probe, cryoablation has
been reported to be less likely to injure the urothelium than
heat-based systems, as the cryodamaged collecting system
heals by secondary intention in a watertight fashion.30 In a
retrospective review of 67 cases that involved the ice ball
overlapping the renal sinus, none of the cases were compli-
cated by collecting system injury.31 However, stenosis or
complete occlusion of the ureter is still a possible complica-
tion.32 Therefore, if the ureter appears to be in close proximity
to the planned area of ablation (common with lower pole
lesions), protective maneuvers such as warming the collect-
ing system via a previously placed ureteral stent,22 displace-
ment of the ureter by hydrodissectionwith sterile saline,33 or
Figure 1 (A) Contrast-enhanced CT image shows an enhancing lesion (arrow) in the upper pole of the right kidney. (B) CT image during placement
of cryoprobes using CT fluoroscopy. Ideally, cryoprobes are placed parallel to one another; however, in this case, the rib prevented ideal geometry.
Therefore, the two probes inserted cephalad to this image were placed parallel, while these probes converged. Care was taken not to directly
puncture the collecting system. (C) Images just cephalad to B show nearly parallel cryoprobes, with the hypodense ice ball (star) converging upon
the contrast within the collecting system (arrow). (D) Hypodense region of cryoablation after removal of the probes seen with no contrast
extravasation. (E) Follow-up MRI at 3 years shows no enhancement of the successfully ablated lesion (arrow). CT, computed tomography; MRI,
magnetic resonance imaging.
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probe retraction34 should be considered. If a ureteral stenosis
or occlusion occurs as a complication of thermal ablation,
then placement of a ureteral or nephroureteral stent is
indicated.
Either general anesthesia or moderate sedation can be
used for percutaneous cryoablation. Tumor location plays a
role in the selection of approach.35 Themajority of tumors can
be treated via a percutaneous approach. Anteriorly located
tumors are the most technically challenging; however, even
difficult anteriorly located tumors can be treated using a
percutaneous approach.36 Hydrodissection can displace ad-
jacent structures and allow for a clear window to the tumor of
interest, aswell as amargin of safety for adjacent structures at
risk for thermal injury (►Fig. 2).22,33 Central tumors remain a
challenging treatment location due to the increased risk of
hemorrhage and potential injury to the renal collecting
system by inadvertent direct puncture.
Percutaneous probe placement is performed under image
guidance, with the modality of choice dependent on the
institution and the operator skill and preference.22 While
magnetic resonance imaging (MRI) can been used to guide
probe placement,37,38 computed tomography (CT) is used at
the authors’ institution, occasionally augmented by ultra-
sound depending on the technical situation. CT is used to
monitor ice ball formation during freeze–thaw cycles, as
ultrasound is limited by the acoustic shadow created by ice
ball formation. Either contrast-enhanced CT or MRI can be
used for follow-up imaging, althoughMRI offers the benefit of
not using ionizing radiation. Imaging follow-up is tradition-
ally done at 3, 6, 9, 12, and 18months, and then annually until
5 years.22 While specific imaging follow-up intervals may
vary slightly from institution to institution, 5-year imaging
follow-up should always be completed.
Most long-term oncologic data are limited to single insti-
tution reports with restricted patient numbers and follow-up
periods. The available series suggests that cryoablation has
high efficacy and lowmorbidity, and that oncologic control is
promising.39 From several prior studies, cryoablation of small
RCC has achieved 96.9 to 100% treatment effectiveness rate,
1.3 to 5.2% local tumor progression rate, and 94.1 to 100%
overall survival rate.25,40–42 A recent prospective single arm
study following 134 consecutive patients treated using per-
cutaneous cryoablation for biopsy-proven RCC was pub-
lished.43 Patients were followed up for 5 years. The 5-year
efficacy of percutaneous cryoablation reached 97%, compara-
ble to that of partial nephrectomy. Overall 5-year survivalwas
97.8% and cancer-specific 5-year survival was 100%.43 These
data suggest that in select patients, percutaneous cryoabla-
tion offers similar oncologic efficacy as the gold standard
surgical options of radical or partial nephrectomy.
Figure 2 (A) A 38-year-old woman with tuberous sclerosis and prior right nephrectomy for renal cell carcinoma found to have a 1.1-cm enhancing
left renal mass (arrow). Note the immediately adjacent colon (star). (B) Insertion of 21-gauge needle allows hydrodissection to be performed with
injection of sterile water (arrow) to displace the adjacent colon away from the targeted lesion. (C) RFA electrode positioned under CT guidance,
just prior to final position across the lesion. (D) RFA electrode in final position across the lesion with colon successfully displaced. CT, computed
tomography; RFA, radiofrequency ablation.
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Cryoablation is a minimally invasive modality that is
reasonably safe, but that has some inherent risk. Data re-
ported from a multicenter retrospective study show major
and minor complication rates of 1.8 and 9.2%, respectively.
Major complications included postprocedure ileus, life-
threatening hemorrhage, conversion to open surgery, urinary
leakage, and scarring of the ureteropelvic junction with
stenosis or obstruction.44 A meta-analysis comparing percu-
taneous to surgical tumor ablation reported a major compli-
cation rate of 3% in the percutaneous group, compared with a
complication rate of 7% in the surgical group. Major compli-
cations after percutaneous ablation included hematuria with
blood loss, ureteric injury, cutaneous fistula, colonic injury,
and seeding of the needle tract.28 A recent retrospective
review of complications from percutaneous renal ablation
using both radiofrequency ablation (RFA) and cryoablation
reported a major complication rate of 7.4% for cryoablation.
The major complications were hemorrhage and hematuria,
occurring 4.8 and 2.6%, respectively.45
Radiofrequency Ablation
Heat used as a medical tool dates back to prehistoric times
when hot stones were used to achieve hemostasis.46 Around
3,000 BC, the Egyptians used cautery to treat tumors, while
Hippocrates later described using it for a variety of common
conditions, including shoulder dislocations and hemor-
rhoids.47 Much later, around the turn of the 20th century,
electricitywas used to treat awide arrayof conditions ranging
from insomnia to circulatory ailments to skin cancers, and a
variety of terms were used to describe these remedies,
including diathermy, fulguration, electrocoagulation, and
desiccation.46 Perhaps the best known application of electri-
cal current in medicine was when Harvey Cushing and
William T. Bovie47 combined forces to use Bovie’s electrosur-
gical device to provide hemostasis during the resection of a
vascular brain tumor in 1926. Since then, alternating high-
frequency current has been adapted for a multitude of uses,
including the ablation of solid tumors. The first hepatic
ablations48,49 were described in 1990, and the first renal
ablation50 in 1997.
RFA employs a generator to create an alternating current,
typically with a frequency of approximately 500 kHz,51 via an
electrode that is placed in the targeted tumor. Grounding
pads applied to the patient complete the circuit. This alter-
nating current creates agitation of ions in the tissues near the
tip of the probe, which results in intense frictional heat that
spreads outward by conduction into the adjacent tissues.
Coagulative necrosis then occurs in the tumor and surround-
ing margins once sufficient heating occurs.52 The zone of
ablation is limited to the area of active heating surrounding
the electrode. When tissue is heated to above 49°C, cell death
occurs within minutes.53 Temperatures of 60 to 100°C result
in immediate cell death by denaturation of proteins, loss of
enzymatic function, melting of cell membranes, and destruc-
tion of cytoplasm.53,54 Desiccation or charring of tissues can
occur with rapid or excessive heating to greater than 100°C,
when tissue vaporization and carbonization occurs, inhibit-
ing conduction of heat.54,55 Several mechanisms are used to
control and limit the heat produced by the probe, including
internal liquid cooling of the electrode, and pulsed energy
delivery.53 Several RFA systems are currently available using
either temperature or impedance-based algorithms.54 Tem-
perature-based systems determine endpoint by monitoring
probe temperature, which once reached is maintained for a
prescribed time based on desired size of the ablation zone.
Impedance-based systems determine the treatment endpoint
by monitoring tissue impedance to the emitted radiofre-
quency current. Depending on the manufacturer, once the
impedance in the tissue rises significantly above baseline, the
system either shuts off temporarily to facilitate gradual
heating of the tissue before restarting or shuts down entirely
signaling completion of the ablation.54
Investigators have compared surgical and percutaneous
introduction of RFA probes. Typically, CT or ultrasound guid-
ance is used to percutaneously introduce electrodes, while CT
is best for intermittently monitoring of the ablation zone
during the procedure, as it has the advantage of easily imaging
adjacent structures (bowel, ureter, and pancreatic tail) to avoid
nontarget injury. One study describes a retrospective follow-
up of 115 patients (51 patients undergoing RFA, 54 patients
undergoing radical nephrectomy, and 10 patients undergoing
partial nephrectomy).56 While overall survival differed in this
study, cancer-related survival following RFA was 100% at
5 years, the same as both partial and radical nephrectomy,
and disease-free survival was 98% at 5 years, also similar to
surgery. The percent decrease in glomerular filtration ratewas
significantly lower in the RFA group (7.9%) compared with
radical nephrectomy (29.0%, p < 0.001), and similar to
the partial nephrectomy group (11.5%, p ¼ 0.73).56 A separate
5-year retrospective study comparing RFA (both percutaneous
[n ¼ 25] and laparoscopic [n ¼ 12]) and partial nephrectomy
(both laparoscopic [n ¼ 28] andopen [n ¼ 9])with 37patients
in each arm also reported no significant difference between
5-year oncologic survival cancer-specific survival, and disease-
free survival.57 Of note, there was no statistically significant
difference in oncologic outcomes between the two RFA
groups.57
Similar to cryoablation, sedation or general anesthesia can
be used to perform RFA. General anesthesia allows for com-
plete respiratory control during probe placement and has
been shown to optimize patient tolerance during abla-
tion.58,59 Tumor size and location are both predictors of
success of RFA.60 RFA is less successful for centrally located
hilar tumors, due to the heat sink effect.61 Anterior lesions, as
with any percutaneous ablation, are technically difficult
tumors to treat. Hydrodissection with sterile water has
been described as a technique to assist in thermal protection
of adjacent structures.62 Other thermal protective measures,
including CO2 instillation and the use of balloons, have been
described as well.63 Recent series suggests that transhepatic
RFA may also be safe for the treatment of difficult to access
right-sided tumors.64 Follow-up imaging with either CT or
MRI is performed as described earlier for cryoablation.
Long-term oncologic control data are maturing for RFA.
Zagoria et al showed durable oncologic control for RCCs
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smaller than 4 cm, with no local recurrences in this group
during a median follow-up of 61 months.59 The local recur-
rence-free, disease-free, and overall 5-year survival after
initial RFA were 88, 83, and 66%, respectively. Another inves-
tigation of renal RFA, with an average tumor size of 2.4 cm,
found 5-year actuarial metastasis-free and cancer-specific
survival rates of 95 and 99%, respectively.65 A recent study
of 58 healthy adults undergoing RFA for treatment of T1a
tumors showed excellent long-term outcomes. Mean tumor
size in this study was 2.2 cm. Five- and 10-year recurrence-
free survival rates were 94.2%, and 5- and 10-year overall
survival rates were 95.7 and 91.1%, respectively.66 Wah et al
recently published a case series of 200 patients undergoing
RFA for RCC, with a mean tumor size of 2.9 cm. Overall
technical success rate was 98.5%. Five-year overall cancer
survival rate was 75.8%, cancer-specific survival rate was
97.9%, and metastasis-free survival rate was 87.7%.67 A
second smaller series of 62 patients published by Balageas
et al reported a primary technical success rate of 95.2%;
disease-free survival rate of 88.3 and 61.9% at 3 and 5 years,
respectively; and a major complication rate of 5.9%.68
In a meta-analysis performed by Hui et al, the major
complication rate of percutaneous RFA was 3.1%, versus
7.4% associated with open surgical approaches. In this analy-
sis, percutaneous ablation also conferred a shorter hospital
stay.28 Peripheral and exophytic lesions are more safely
treated than centrally located lesions, while hemorrhage is
the most commonly reported complication following renal
RFA. Minor perinephric hematomas are common, but life-
threatening hemorrhage is rare. Theoretically, renal infarc-
tion should be an expected complication following renal RFA;
however, this complication is exceedingly rare.69 Collecting
system injury is also possible, with the proximal ureter being
the most commonly injured segment. When this results in
ureteral stricture and hydronephrosis, stent placement is
necessary. Again, this can be avoided by various techniques
including cooling the collecting system via a previously
placed ureteral stent.22 Thermal injury to adjacent structures
is also described, including injury to adjacent small bowel. If
necessary, hydrodissection with sterile water, CO2 insuffla-
tion, or balloon placement can protect adjacent structures.
Injury to nerves, such as the ilioinguinal, iliohypogastric, or
genitofemoral nerves that are in close proximity to the psoas
muscle, has also been described.70
Cryoablation versus Radiofrequency
Ablation
A meta-analysis published by El Dib et al71 evaluated 31 case
series of cryoablation and RFA. The pooled data demonstrated
clinical efficacy of 89% for cryoablation and 90% for RFA, with no
significant difference in complication outcomes.71 Pirasteh et al
conducted a retrospective comparison between cryoablation
and RFA comparing recurrence rates between the two modali-
ties. Reported recurrence rates based on imaging were 11% for
RFA and 7% for cryoablation, which did not reach statistical
significance.72 It should be kept in mind that any difference in
recurrence-free survival between cryoablation and RFA is likely
small (< 5%), and that it would require a multi-institutional,
randomized trial to confidently detect this difference.73
Truesdale et al compared the dose of sedation medication
used for patients undergoing either cryoablation or RFA of
renal tumors, and found that cryoablation was performed
with fewer medications than RF.74 The less painful nature of
cryoablation and the ability to visualize the ice ball during the
ablation are advantages of cryoablation. Conversely, RFA
allows one to cauterize the ablation tract, an advantage
that may diminish the risk of significant hemorrhage and
tract seeding. Operator preferences and experiencewill likely
continue to guide the selection of ablation devices, while
10-year recurrence rates are identified through registries.73
Microwave Ablation
Microwave ablation has been studied extensively for the
treatment of liver masses. Microwave energy causes cell death
by agitation of water molecules, resulting in frictional heat. An
oscillating electromagnetic field in the 900- to 2,450-MHz
frequency range is generated by a probe inserted into the
tumor bed using image guidance. Dipolar water molecules
attempt to orient within the induced electromagnetic field. As
thefield oscillates,watermolecules attempt to realignwith the
field creating frictional kinetic energy transformed to heat
sufficient to cause cell death via coagulative necrosis.75 Unlike
RFA, microwaves propagate through all forms of tissue, includ-
ing charred and desiccated tissues, resulting in higher temper-
atures achieved in a shorter time frame and allowing for more
uniform tissue necrosis.76 Because of the thermal profile, the
problem with heat sink occurring in RFA when tumors are
adjacent to large vessels is minimized.
A recent intermediate-term follow-up of 46 patients who
underwent microwave ablation for treatment of RCC showed
promising outcomes up to 3 years, with technical effectiveness
of microwave of 98%, 3-year local tumor progression rate of
7.7%, and cancer-specific survival at 3 years of 97.8%.77 This is
comparable to outcomes for cryoablation and RFA. However, a
recent study showed disappointing results for microwave
ablation of tumors with amean size of 3.65 cm.78 In this study,
the tumor recurrence rate was 38% at 18-month follow-up. In
addition, the complication rate was 20% intraoperatively and
up to 40% postoperatively.78 Tumor characteristics and small
sample size may have played a role in these outcomes. A
separate, recent, single-center prospective randomized study
compared microwave ablation to partial nephrectomy.79 This
study reported local recurrence-free survival rates at 3 years of
91.3% for microwave versus 96% for partial nephrectomy
(p ¼ 0.5414). Microwave demonstrated significantly reduced
blood loss, lower complication rates, but worsening postoper-
ative renal function compared with partial nephrectomy.
Surgical and hospitalization times were comparable.79
Irreversible Electroporation
Irreversible electroporation (IRE) is a nonthermal ablation
process by which microscopic pores are created within cell
membranes from the application of rapid electrical pulses,
Seminars in Interventional Radiology Vol. 31 No. 2/2014



















































resulting in cell death.80,81 This permeabilization of the cell
membrane can be reversible or irreversible. Reversible elec-
troporation allows the delivery of a variety of materials such
as fluorescent dyes, chemotherapeutic agents, antibodies,
enzymes, and DNA, while IRE renders the cell necrotic by
induction of instabilities in the lipid bilayer of the cell
membrane.80,81 By modulating electricity across the cell,
IRE impacts the cellular membranes of the target tissues
but may spare adjacent connective tissue. This potentially
offers advantages over thermal ablation modalities, which
carry the risk of injury to the collecting system.82–86 While
both animal and human studies have demonstrated a relative
sparing of the urothelium with IRE, additional studies are
warranted.82,83,85,86 In addition, because IRE is a nonthermal
modality, it is not susceptible to the “heat sink” effect of
adjacent vessels.82,86 While attractive for these reasons, IRE
has several drawbacks. The potential for inducing cardiac
arrhythmias and muscle contractions requires electrocar-
diographic monitoring and synchronization, and general
anesthesia with deep neuromuscular blockade.20,85,87 More-
over, the inability to cauterize the entry tract potentially
increases the risk of bleeding and tract seeding.20,85
IRE has been investigated in several different organs,
including the liver, pancreas, lung, and kidney.81,83–86 Multi-
ple animal studies have demonstrated safety in treating renal
tumors.81–83,86 A phase I clinical study in humans was
performed in patients who were undergoing surgical resec-
tion of their RCCs (IRE followed by immediate resection), and
this demonstrated that IRE for RCC was feasible and safe.88
While histopathologic analysis was performed, this only
demonstrated that the cells had begun to swell, as the tissue
was resectedwithin 15minutes of electroporation.88 Safety of
IRE was again demonstrated in 2011 by Thomson et al who
investigated ablation of liver, kidney, and lung lesions in 38
patients.85 Recently, a retrospective study also found IRE to be
safe and the learning curve to be acceptable.87 Given that IRE
is not susceptible to the thermal impact of adjacent vessels
and that there is potential for relative urothelial protection,
further investigation is warranted in the kidney for this
promising ablation modality.
High-Intensity-Focused Ultrasound
High-intensity-focused ultrasound (HIFU) is based on the
physical effects of ultrasound energy on tissue. A focused
ultrasound beam is progressively absorbed and its mechani-
cal energy converted to heat.89,90 The thermal effect induces
rapid temperature rise at the ultrasound focus point, result-
ing in protein denaturing and coagulative necrosis, while
sparing the superficial tissues and surrounding parenchyma.
A secondary cavitation effect also occurs, where microbubble
formation results in mechanical tissue lysis from high pres-
sure.89 Both intra- and extracorporeal systems exist; intra-
corporeal systems are used in open and laparoscopic surgery,
while extracorporeal systems are image guided using ultra-
sound or MRI.89,90
Results of clinical trials using HIFU for treating renal
masses have been disappointing.89,91–93 Seven tumors
(average size of 22 mm) in seven patients treated with
laparoscopic, intracorporeal HIFU with “curative intent” be-
fore partial nephrectomy showed complete ablation in only
four of the seven patients. An eighth patient who did not
undergo partial nephrectomy was followed up with imaging
and had no evidence of disease at 6 months.91 In another
study, 16 patients were treated with HIFU, 2 for curative
intent and 14 before surgical removal. Histopathologic review
of the explanted tumors showed only 9 of 14 showing
therapeutic necrosis, and the histologically damaged tissue
comprised only 15 to 35% of the targeted tissue.92 In a similar
study, 19 patients were treated before tumor explantation.
Thermal damages of the tissues were variable and poor,
partially seen in 15 of 19 cases.93
These trials show that extracorporeal HIFU has several
technical limitations at present, including variable target
tissue depth, respiratory motion, and limitations secondary
to tissue variability.89,92,93 A trial using laparoscopic intra-
corporeal approach appears to have mitigated some of these
effects; however, further data are necessary to validate this
new technique.91
Conclusion
Several ablative modalities are available that use thermal and
nonthermal means to achieve therapeutic tissue necrosis.
While data regarding their long-term oncologic efficacy are
still evolving, some have been incorporated into clinical
guidelines as treatment alternatives for select patients. Cry-
oablation and RFA have been studied the most, demonstrat-
ing favorable safety and efficacy profiles compared with
surgical options. Differences between RFA and cryoablation
seem to be negligible with respect to intermediate-term
oncologic outcomes and complications. Microwave ablation
could potentially offer an advantage for central tumors be-
cause of its ability to overcome the heat sink effect. IRE offers
the potential advantage of targeted therapy to tumor cells
while sparing tissue surrounding the urothelium; however,
requirements for general anesthesia and electrocardiograph-
ic synchronization make its use logistically challenging. HIFU
is a relatively new modality, and requires further evaluation
to determine its treatment efficacy.
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